Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Presentation
Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose rangeInvikafusp alfa


